Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Broad-Based Characterization of a Cell-Penetrating, Single Domain Camelid Bi-Specific Antibody Monomer That Targets STAT3 and KRAS Dependent Cancers.

International journal of molecular sciences - 8 Jul 2022

Singh Sunanda, Murillo Genoveva, Richner Justin, Singh Samara P, Berleth Erica, Kumar Vijay, Mehta Rajendra, Ramiya Vijay, Parihar Ashutosh S

Abstract excerpt

STAT3 and KRAS regulate cell proliferation, survival, apoptosis, cell migration, and angiogenesis. Aberrant expression of STAT3 and mutant active forms of KRAS have been well-established in the induction and maintenance of multiple cancers. STAT3 and KRAS mutant proteins have been considered anti-cancer targets; however, they are also considered to be clinically "undruggable" intracellular molecules, except for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Bispecific
Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Apoptosis

Share to Cell Proliferation

Share to Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Single-Domain Antibodies

Share to STAT3 Transcription Factor

Source

Open in PubMed Open full text

Identifiers

PMID: 35886918
DOI: 10.3390/ijms23147565
PMCID: PMC9323098

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Broad-Based Characterization of a Cell-Penetrating, Single Domain Camelid Bi-Specific Antibody Monomer That Targets STAT3 and KRAS Dependent Cancers.PMID 35886918Read ↗

The JAK/STAT3 axis: A comprehensive drug target for solid malignancies.Semantic proximity Read ↗

Site-directed antibodies targeting driver mutations of the KRAS protein.Semantic proximity Read ↗

Selective and noncovalent targeting of RAS mutants for inhibition and degradation.Semantic proximity Read ↗

Small Molecule Inhibitors of STAT3 for Cancer TherapySemantic proximity Read ↗

Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discoverySemantic proximity Read ↗

A pan-KRAS degrader for the treatment of KRAS-mutant cancersSemantic proximity Read ↗

Small molecule STAT3/5 inhibitors exhibit therapeutic potential in acute myeloid leukemia and extra-nodal natural killer/T cell lymphomaSemantic proximity Read ↗

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor.Semantic proximity Read ↗

Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic CancerSemantic proximity Read ↗

Mutated RAS: Targeting the “Untargetable” with T CellsSemantic proximity Read ↗

Nanobody-based therapeutics against colorectal cancer: Precision therapies based on the personal mutanome profile and tumor neoantigens.Semantic proximity Read ↗

CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.